Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000358 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
A Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00000358 is a Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.
The verdict
NCT00000358, a Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
Conditions Studied
Interventions
- DRUG Lofexidine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000358
The ClinicalTrials.gov registry entry for NCT00000358 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Lofexidine is the first listed.
NCT00000358 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00000358 about?
NCT00000358 is a clinical study titled "Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7". The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
What is the current status of trial NCT00000358?
This trial is currently completed. It is a Phase 1 study.
What conditions does trial NCT00000358 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders.
What interventions are being tested in trial NCT00000358?
The interventions under investigation include: Lofexidine (DRUG).
Who is sponsoring clinical trial NCT00000358?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000358 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Clinical Trial of Computer-based Motivational Intervention - 1
COMPLETED · Phase 1
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
-
Cognitive Therapy for PTSD in Addiction Treatment
COMPLETED · Phase 1
-
Prepulse Inhibition of Startle in Cocaine Dependence - 7
COMPLETED · Phase 1
-
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.